Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 14776 - 14800 of 14856 in total
Experimental
Illicit
Oglemilast has been investigated for the treatment of Pulmonary Disease, Chronic Obstructive.
Investigational
Experimental
UK-500,001 has been used in trials studying the treatment of Pulmonary Disease, Chronic Obstructive.
Investigational
Setrobuvir has been used in trials studying the treatment of Hepatitis C, Chronic.
Investigational
PRLX 93936 is selectively toxic to cancer cells.
Investigational
Gantacurium chloride is a new, investigational, non-depolarizing ultra-short acting neuromuscular blocker. It is being developed by Avera Pharmaceuticals.
Investigational
XL019 is a selective inhibitor of the cytoplasmic tyrosine kinase JAK2. An IND for XL019 was filed by Exelixis in May 2007.
Investigational
ALS-08 is a proprietary creatine-derivative that is being developed as a potential therapeutic for amyotrophic lateral sclerosis (ALS). It is being developed by Avicena Group, Inc.
Investigational
105AD7 is a human monoclonal antibody that mimics the complement regulatory protein, CD55, overexpressed by many solid tumours including osteosarcoma. 105AD7 induced antitumour inflammatory responses in metastatic colorectal cancer patients. 105AD7 may be a suitable vaccine for treatment of this disease.
Investigational
NRP409 is a triiodothyronine (T3) hormone, being investigated by New River Pharmaceuticals as a treatment for patients with primary hypothyroidism.
Investigational
Displaying drugs 14776 - 14800 of 14856 in total